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Aim To investigate the prevalence of common genetic 
variants that can serve as markers of thrombophilia and 
warfarin pharmacogenetics in Bosnia and Herzegovina.
Methods The study was performed between August and 
October 2017 on 130 healthy unrelated adult volunteers 
from Bosnian-Herzegovinian population sample. The prev-
alence of the following genetic variants was determined: 
F5 c.1601G>A (factor V Leiden), F2 c.*97G>A (factor II or 
prothrombin mutation), F13A1 (factor XIII) c.103G>T, MTH-
FR (methylenetetrahydrofolate reductase) c.665C>T and 
c.1286A>C, as well as PAI-1 (plasminogen activator inhibi-
tor 1) c.-816A>G and c.-844G>A as markers of thrombo-
philia risk, and *2 and *3 alleles of CYP2C9 (cytochrome 
P450 2C9) and five variants of VKORC1 (vitamin K epoxide 
reductase complex subunit 1) as markers of warfarin phar-
macogenetics. DNA was isolated from buccal swabs using 
salting out method, while genotyping was performed us-
ing matrix-assisted laser desorption/ionization-time-of-
flight mass spectrometry.
Results Minor allele frequencies for two main thrombo-
philia risk factors, F5 c.1601G>A and F2 c.*97G>A were 
0.023 and 0.008, respectively. Combined data for the mark-
ers of warfarin pharmacogenetics imply that 57.4% study 
participants can be expected to metabolize warfarin at an 
extensive, 40.3% at intermediate, and 2.3% at a poor rate.
Conclusion This study reports the first extensive popula-
tion genetic data for thrombophilia and warfarin pharma-
cogenetic markers in Bosnia and Herzegovina. Allele fre-
quencies of genetic variants are within the general average 
for European populations, and their presence implies the 
necessity of introduction of personalized medicine in war-
farin-mediated antithrombotic therapy.
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Thrombophilia is a condition conferring the risk of venous 
or arterial thrombosis and can be roughly classified into 
hereditary and acquired. Hereditary thrombophilia en-
compasses loss-of-function and gain-of-function genetic 
variants. Deregulation of coagulation cascade caused by 
loss-of-function variants, as well as their penetrance level, 
makes them more severe than gain-of-function variants, 
which are, however, around 10-fold more common in the 
general population (1,2). Currently, seven variants in five 
genes are routinely genotyped as genetic risk factors of in-
herited thrombophilia: F5 c.1601G>A (factor V Leiden, FVL), 
F2 c.*97G>A (factor II G20210A or PTM, prothrombin mu-
tation), two MTHFR (methylenetetrahydrofolate reductase) 
variants, two PAI-1 (plasminogen activator inhibitor 1) vari-
ants, and F13A1 (factor XIII) c.103G>T (FXIII, V35L) (3-9). War-
farin, a coumarin derivative and vitamin K antagonist (VKA), 
is an oral anticoagulant taken to limit the production of co-
agulation factors II, VII, IX, and X. It is used for the preven-
tion and treatment of thromboembolic events in patients 
with previous thromboembolism and atrial fibrillation (AF), 
following the implantation of artificial heart valves and vas-
cular bypass procedures, as well as due to major orthope-
dic surgery (10-14).
Warfarin-mediated anticoagulation is currently considered 
to be a risky clinical therapy due to numerous interactions 
and interpatient variations in mean daily warfarin dose 
and narrow drug therapeutic range (10,12,13). We there-
fore hypothesized that a significant percentage of individ-
uals from the general population will have minor variants 
in genes involved in thrombophilia risk, as well as warfarin 
pharmacodynamics and pharmacokinetics.
The aim of this study was to analyze the frequency of mu-
tant alleles in two abovementioned sets of markers in 
Bosnia and Herzegovina (B&H). Additionally, we aimed to 
propose a simple and affordable method for genotyping 
relevant genetic variants that enables successful and safe 
implementation of personalized warfarin treatment in rou-
tine clinical practice.
MATERIALS AND METHODS
Sample collection and DNA isolation
Buccal swab samples were collected from 130 unrelated 
adult volunteers from B&H. Sample collection was per-
formed in the medical laboratory Prolab (Sarajevo, B&H) 
between August and October 2017. Laboratory users 
were asked to participate in the study if they had no his-
tory of thrombotic events. In order to achieve a balanced 
distribution of participants’ demographic characteris-
tics we included participants of both sexes, different age 
groups, and originating from different parts of the coun-
try as assessed by the origin of their grandparents. The 
size of the study population was determined according 
to previous population studies conducted in B&H (15,16) 
and was affected by financial constraints. Before agreeing 
to participate in the study, all participants signed the in-
formed consent for study participation and data publica-
tion. Participants’ identity was known only to the main in-
vestigators. Ethical approval was obtained from the Ethics 
Committee of the International Burch University (Saraje-
vo, B&H) on July 6, 2017, document number 04-172-1/17. 
Genomic DNA was isolated from buccal swab samples 
using modified Miller’s protocol (17) at the International 
Burch University.
Genotyping procedure
All genotyping procedures were performed in Bioglobe 
Laboratory, Hamburg, Germany. In order to analyze throm-
bophilia markers and pharmacogenetic markers of warfa-
rin metabolism, two multiplexes and one uniplex iPLEX as-
says were set-up as follows:
1. Multiplex reaction for seven thrombophilia markers, in-
cluding F5 c.1601G>A, F2 c.*97G>A, MTHFR c.665C>T and 
c.1286A>C, PAI-1 c.-816A>G and c.-844G>A, and F13A1 
c.103G>T;
2. Multiplex reaction for six markers of warfarin pharma-
cogenetics: VKORC1 (vitamin K epoxide reductase complex 
subunit 1) c.-1320G>A, VKORC1 c.-1639G>A, VKORC1 c.-679-
A>G, VKORC1 c.174-136C>T, VKORC1 c.283 + 124G>C and 
CYP2C9 (cytochrome P450 2C9) c.1075A>C (CYP2C9*3);
3. Uniplex reaction for the marker of warfarin metabolism 
CYP2C9 c.430C>T (CYP2C9*2).
Primer selection and plex design was performed in Assay 
Design Suite v2 (Agena Bioscience, San Diego, CA, USA). 
PCR reactions were set-up in 384-well plate with reaction 
components and thermal cycling conditions as previ-
ously described (18). In order to remove leftover dNTPs, 
shrimp alkaline phosphatase (SAP) treatment was em-
ployed as previously described (18). A general iPLEX re-
action setup and cycling protocol was employed for all 
plexes using single-base extension chemistry and ac-
cording to Storm et al (18) using 75 cycles. Thermal 
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cycling was performed in GeneAmp PCR System 9700 
(Applied Biosystems, Waltham, MA, USA).
Ion exchange sample conditioning was performed to re-
move excess cations from the sample-containing wells 
using Clean Resin (Agena Bioscience) (18). 15-nL samples 
were transferred to SpectroCHIP using MassARRAY Nano-
dispenser controlled by iPlex Genotyping for MassARRAY 
Nanodispenser software by Agena Bioscience. Matrix-as-
sisted laser desorption/ionization-time-of-flight mass spec-
trometry measurement and genotyping of the products 
of iPLEX reactions were performed by using two software 
packages (both by Agena Bioscience): SpectroACQUIRE to 
obtain spectra and raw data and MassARRAY Typer to de-
sign sample plates and study assays, and access and export 
genotype data.
Statistical analyses
Testing for Hardy-Weinberg equilibrium (HWE) was per-
formed in GenAIEx v. 6.5 (http://biology-assets.anu.edu.
au/GenAlEx/Welcome.html) using χ2 statistics at the sig-
nificance level of 0.05 (19,20). Linkage disequilibrium (LD) 
testing was performed in a pairwise manner using the on-
line version of GenePop v. 4.2 (http://genepop.curtin.edu.
au/) at the significance level of 0.01 (21,22). Descriptive sta-
tistics for the study population and associations between 
demographic parameters and gene variants were calculat-
ed using IBM SPSS Statistics for Windows v. 23.2 (IBM Corp., 
Armonk, NY, USA), with Fisher exact test used at the signifi-
cance level of 0.05.
RESULTS
The group of elderly participants was underrepresented, 
with 6.2% sample donors being older than 60 years, since 
the majority of laboratory users who rejected to participate 
were from this age group (Table 1). Genotype data were 
successfully generated for all 130 participants for throm-
bophilia markers and for 129 participants for pharmacoge-
netic markers of warfarin metabolism.
Allele frequencies for two most significant markers of inher-
ited thrombophilia were 0.023 and 0.008 for F5 c.1601G>A 
and F2 c.*97G>A, respectively. Neither age nor sex were 
significant predictors of variant thrombophilic marker dis-
tribution (Table 2) (Fisher exact test, P values for association 
with age: P = 0.645 for F5 c.1601G>A, P = 0.840 for MTHFR 
c.665C>T, P = 0.160 for PAI-1 c.-844G>A, and P > 0.999 for 
the remaining variants; P values for association with sex: 
P = 0.190 for F5 c.1601G>A, P = 0.461 for MTHFR c.665C>T, 
P = 0.419 for PAI-1 c.-816A>G, P = 0.533 for F2 c.*97G>A, 
P = 0.366 for MTHFR c.1286A>C, P = 0.451 for PAI-1 c.-844-
G>A, and P > 0.999 for F13A1 c.103G>T). All study loci were 
in agreement with HWE (χ2 test, P > 0.05 for all seven loci). 









>60  8 (6.2)
Region
Bosnian Krajina and Western Bosnia 20 (15)
Central Bosnia 52 (40)
Eastern Bosnia 38 (29)
Herzegovina 20 (15)
TAbLE 2. Genotype frequencies (with absolute genotype numbers in parentheses) and allele frequencies of risk markers of thrombo-
philia in bosnian-Herzegovinian population. Allele frequency values are presented as major and minor allele frequencies*
Genotype frequency, % (n) Allele frequency
Variant major homozygous heterozygous minor homozygous major minor
FVL (F5 c.1601G>A) 95.4 (124)  4.6 (6)  0.0 (0) G 0.977 A 0.023
MTHFR C677T (c.665C>T) 43.8 (57) 46.2 (60) 10.0 (13) C 0.669 T 0.331
PAI-1 4G/5G (c.-816A>G) 30.0 (39) 50.8 (66) 19.2 (25) 4G 0.554 5G 0.446
FII G20210A (F2 c.*97G>A) 98.5 (128)  1.5 (2)  0.0 (0) G 0.992 A 0.008
MTHFR c.1286A>C 46.2 (60) 43.1 (56) 10.8 (14) A 0.677 C 0.323
PAI-1 c.-844G>A 15.4 (20) 51.5 (67) 33.1 (43) G 0.412 A 0.588
F13A1 c.103G>T (V35L) 50.0 (65) 36.9 (48) 13.1 (17) G 0.685 T 0.315
*F2, FII – factor II, F5 – factor V, F13A1 – factor XIII variant A1, FVL – factor V Leiden, MTHFR – methylenetetrahydrofolate reductase, PAI-1 – plasmino-
gen activator inhibitor 1.
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Using log likelihood ratio, two pairs of loci were found to 
be in strong linkage disequilibrium: 1) MTHFR c.665C>T 
and MTHFR c.1286A>C and 2) PAI-1 c.-816A>G and PAI-1 c.-
844G>A (P < 0.01 in both cases).
Genotype data for markers of warfarin pharmacogenet-
ics (Table 3) revealed that all polymorphic loci were in 
agreement with HWE (P > 0.05 for all five loci), while age 
and sex were not significantly associated with variant al-
lele incidence (P values for association with age: P = 0.493 
for CYP2C9 c.430C>T and P > 0.999 for the remaining poly-
morphic loci; P values for association with sex: P = 0.294 
for CYP2C9 c.430C>T, P = 0.342 for CYP2C9 c.1075A>C and 
P > 0.999 for the remaining three polymorphic loci). Three 
analyzed polymorphic VKORC1 loci, c.-1639G>A, c.174-
136C>T, and c.283 + 124G>C, were in complete linkage 
disequilibrium (P < 0.001). Statistical tests were employed 
only for the loci found to be polymorphic.
To determine the classes of warfarin metabolism according 
to metabolization rate (rapid, normal/extensive, intermedi-
ate or poor rate) (23), joint analysis of CYP2C9 c.430C>T and 
c.1075A>C and VKORC1 c.-1639G>A genotypes was per-
formed (Table 4). A total of 57.4% study participants were 
classified as extensive metabolizers of warfarin. The rest of 
the participants were classified as warfarin-sensitive, that 
TAbLE 3. Genotype frequencies (with absolute genotype numbers in parentheses) and allele frequencies of markers of warfarin phar-
macogenetics in bosnian-Herzegovinian population. Allele frequency values are presented as major and minor allele frequencies*
Genotype distribution, % (n) Allele frequency
Variant major homozygous heterozygous minor homozygous major minor
CYP2C9*2 (c.430C>T)  74.4 (96) 24.8 (32)  0.8 (1) C 0.868 T 0.132
CYP2C9*3 (c.1075A>C)  82.9 (107) 16.3 (21)  0.8 (1) A 0.911 C 0.089
VKORC1 c.-1639G>A  39.5 (51) 45.7 (59) 14.7 (19) G 0.624 A 0.376
VKORC1 c.-1320G>A 100.0 (129)  0.0 (0)  0.0 (0) G 1.000 A 0.000
VKORC1 c.-679A>G 100.0 (129)  0.0 (0)  0.0 (0) A 1.000 G 0.000
VKORC1 c.174-136C>T  39.5 (51) 45.7 (59) 14.7 (19) C 0.624 T 0.376
VKORC1 c.283 + 124G>C  39.5 (51) 45.7 (59) 14.7 (19) G 0.624 C 0.376
*CYP2C9 – cytochrome P450 2C9, VKORC1 – vitamin K epoxide reductase complex subunit 1.
TAbLE 4. Combined VKORC1 c.-1639G>A and CYP2C9*2 and *3 genotypes in the study population from bosnia and Herzegovina 
and genotype classification into extensive, intermediate, and poor metabolizer classes. The prediction of metabolizer class for each 
genotype was done according to Food and Drug Administration (FDA) recommendations from 2015 (23)*
VKORC1 c.-1639G>A genotype CYP2C9 genotype Number of participants (n) Percentage distribution Metabolizer class
GG *1/*1 30 23.3 extensive
*1/*2 11 8.5 extensive
*1/*3 7 5.4 intermediate
*2/*2 0 0.0 N/A
*2/*3 3 2.3 intermediate
*3/*3 0 0.0 N/A
GA *1/*1 33 25.6 extensive
*1/*2 15 11.6 intermediate
*1/*3 9 7.0 intermediate
*2/*2 1 0.8 intermediate
*2/*3 0 0.0 N/A
*3/*3 1 0.8 poor
AA *1/*1 14 10.9 intermediate
*1/*2 3 2.3 intermediate
*1/*3 2 1.6 poor
*2/*2 0 0.0 N/A
*2/*3 0 0.0 N/A
*3/*3 0 0.0 N/A
*CYP2C9 – cytochrome P450 2C9, VKORC1 – vitamin K epoxide reductase complex subunit 1.
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is, requiring daily warfarin dose decrease; 40.3% individuals 
had intermediate metabolism and 2.3% were poor warfa-
rin metabolizers.
DISCUSSION
Thrombophilia risk markers and genetic markers of war-
farin pharmacogenetics were detected in a considerable 
proportion of general Bosnian-Herzegovinian population. 
The calculated allele frequencies are close to the previous-
ly reported European average.
The minor allele frequency of FVL prevalence in our study 
was 0.023. A previously reported FVL prevalence rate in 
healthy individuals in B&H was similar (Table 5). In Central 
Europe (Poland, Slovakia, Czech Republic), the frequency 
of mutant FVL was 0.039. In East Europe (Russia, Ukraine, 
Belarus) it was 0.019, while in South-Eastern Europe (Cro-
atia, Serbia/Serbia and Montenegro, Macedonia, Slovenia, 
Bulgaria), it was 0.025 (30). A somewhat lower FVL preva-
lence was reported by the 1000 Genomes Project phase III 
data (Table 6) (31). MAF for F2 c.*97G>A (PTM) of 0.008 in 
the present research is in agreement with previous stud-
ies in B&H and worldwide (Tables 5 and 6), in which mi-
nor allele was either the least abundant or absent from the 
population.
MTHFR variants are globally most common in Europeans 
and Hispanics (Table 6), although heterozygous c.665C>T, 
homozygous c.1286A>C, or compound heterozygous 
genotypes currently seem not to have any clinical signifi-
cance in thrombosis testing (9). MTHFR polymorphism is 
not included in the panel for inherited thrombophilia test-
ing by the British Committee for Standards in Haematol-
ogy and the British Society for Haematology. The American 
College of Medical Genetics and Genomics (ACMG) states 
that the informativeness of MTHFR testing is limited, and 
that homocysteine levels should be measured instead. In 
addition, ACMG recommends against MTHFR testing for 
the analysis of inherited thrombophilia, recurrent pregnan-
cy loss, or for at-risk family members (9). c.665C>T variant 
has a prevalence of around 20% in Caucasians and Hispan-
ics, 11% in Asians, and 1% in African-Americans (33). As re-
gards PAI-1 polymorphism c.-816A>G, also known as PAI-1 
4G/5G, the present study reported 5G allele frequency of 
0.446, which is significantly higher than previously report-
TAbLE 5. Summary of previous research of thrombophilic marker prevalence in bosnia and Herzegovina*












Healthy women  67 FVL 0.000 N/A (24)
South-Eastern B&H 
healthy population
207 MTHFR C677T 0.333 N/A (25)




111 DVT patients and 
207 healthy controls
318 FVL 0.0194 in controls and 0.105 in patients
FII G20210A 0.000 in controls and 0.0136 in patients
MTHFR C677T 0.2974 in controls and 0.3384 in patients
FVL variant was significantly more 
common in DVT patients than in 
controls
(27)
154 women who 
experienced PL and 
154 female controls
308 FVL 0.039 in both controls and patients
FII G20210A 0.016 in controls and 0.019 in patients
MTHFR C677T 0.299 in controls and 0.357 in patients
none of three investigated markers 
was significantly correlated with the 
risk of PL
(28)
60 women who 
experienced RPL 
and 80 female controls
140 FVL 0.0188 in controls and 0.075 in patients
FII G20210A 0.0063 in controls and 0.025 in patients
MTHFR C677T 0.25 in controls and 0.3917 in patients
PAI-1 4G/5G 0.2 in controls and 0.3 in patients
significant difference in allele 
distribution between the study 
groups for FVL and MTHFR C677T
(29)
*b&H – bosnia and Herzegovina, DVT – deep vein thrombosis, FII – factor II, FVL – factor V Leiden, FXIIIA1 – factor XIII variant A1, MAF – minor allele 
frequency, MTHFR – methylenetetrahydrofolate reductase, PAI-1 – plasminogen activator inhibitor 1, PL – pregnancy loss, RPL – recurrent pregnancy 
loss.
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ed (Table 5) (29). Marker PAI-1 c.-844G>A had even higher 
prevalence in our population, with -844A allele having the 
frequency of 0.588, which is very close to the European av-
erage of 0.594 (Table 6).
Variant F13A1 c.103G>T, also known as Val35Leu, has been 
assigned a protective role against venous thromboembo-
lism, myocardial infarction (4,8,34), and coronary artery dis-
ease (35). MAF of 0.315 for this marker obtained in the pres-
ent study is somewhat higher than previously reported T 
allele prevalence of 0.242 in Caucasians (Table 6).
Mutations in the latter three genes are considered to have 
additive value to other risk factors, including FVL and PTM 
mutations. Also, PAI-1 variants were found to have a strong 
additive role in the increased incidence of myocardial in-
farction in the presence of metabolic syndrome risk factors, 
such as increased cholesterol and triglyceride levels (36).
VKORC1 variant c.-1639G>A is one of the most extensively 
studied markers of warfarin pharmacodynamics. Its mu-
tant allele A is associated with 2-fold lower gene expression 
and consequential lower warfarin requirements, increased 
risk of bleeding events, and international normalized ra-
tio (INR)>4. The same is true for haplotypes A (warfarin-
sensitive) and B (warfarin-resistant), consisting of c.-1639-
G>A and four additional loci, including c.174-136C>T and 
c.283 + 124G>C, inherited together due to extremely high 
level of linkage disequilibrium (37,38), which was proven in 
the current study as well.
When it comes to worldwide allele frequencies of c.-1639-
G>A, variant allele A is the most frequent in East Asians 
(0.86), followed by Europeans (0.37) and Africans (0.10). 
In US Hispanic population, MAF for this marker was 0.46 
(39). The results from the current study for VKORC1 vari-
ants are in alignment with previously published litera-
ture, especially two previous studies of VKORC1 polymor-
phisms c.1173C>T and c.-1639G>A in Croatia. In the study 
by Mandić et al on 420 unrelated healthy individuals from 
Eastern Croatia, these two loci were in perfect linkage dis-
equilibrium, with major and minor allele frequencies of 
0.593 and 0.407, respectively (40). Another study analyzed 
the same two variants in 186 Croatian patients on stable 
warfarin therapy and found wild-type, heterozygous, and 
mutant homozygous genotypes frequencies to be 33.9%, 
46.8%, and 19.4%, respectively (41).
VKORC1 variants c.-1320G>A and c.-679A>G, together 
with missense change Asp36Tyr from exon 1 of the same 
gene, make up a haplotype that predisposes to high war-
farin requirements, and these variants are more common 
in Jewish individuals than in other ethnic groups (42,43). 
However, these two loci were not polymorphic in general 
Bosnian-Herzegovinian population.
CYP2C9*2 allele (CYP2C9 c.430C>T) was the first CYP2C9 
variant discovered and it stays the most studied SNP on 
this gene. Arg144Cys substitution encoded by this SNP dis-
ables a proper interaction of cytochrome P450 with NA-
DPH-dependent cytochrome P450 oxidoreductase and 
decreases the rate of enzyme activity. Another important 
variant, CYP2C9 c.1075A>C (CYP2C9*3), influences enzyme 
conformation, thus lowering its ability to bind different 
substrates, including warfarin (44). Daly et al report the 
global frequency of allele *2 of 0.0914, while allele *3 is less 
common, with an average worldwide frequency of 0.0637 
(45). A previous population genetic study of CYP2C9 poly-
morphisms in 200 unrelated individuals in Croatian popula-
tion yielded results similar to ours. Alleles *2 and *3 had fre-
quencies of 0.165 and 0.095, respectively (46). In the study 
of 129 healthy Slovenian individuals, alleles *2 and *3 had 
frequencies of 0.122 and 0.063, respectively (47). The only 
previous study on CYP2C9*2 allele in Bosnian-Herzegovin-
TAbLE 6. The summary of the 1000 Genomes Project phase III findings (31). Minor allele frequency of six alleles in five global popula-
tions is given, namely African, admixed American, East Asian, European, and South Asian. Data for PAI-1 4G/5G were not available. 
Complete data set was retrieved from PharmGKb database (32)*
African (n = 1322) Admixed American (n = 694) East Asian (n = 1008) European (n = 1006) South Asian (n = 978)
FVL not detected 0.010 not detected 0.012 0.011
FII G20210A not detected 0.014 not detected 0.008 not detected
MTHFR C677T 0.090 0.474 0.296 0.365 0.119
MTHFR c. 1286A>C 0.151 0.151 0.219 0.313 0.417
PAI-1 c.-844G>A 0.247 0.372 0.393 0.594 0.492
FXIIIA1 V35L 0.164 0.269 0.002 0.242 0.093
*FII – Factor II, FVL – Factor V Leiden, FXIIIA1 – factor XIII variant A1, MTHFR – methylenetetrahydrofolate reductase, PAI-1 – plasminogen activator 
inhibitor 1.
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ian population, which investigated the impact of this allele 
on the susceptibility to type 2 diabetes mellitus (T2DM) by 
genotyping 37 T2DM patients and 44 healthy controls, re-
ported a low mutant allele frequency of 0.09) (48).
Novel or direct oral anticoagulants (NOACs, DOACs) are 
presently considered as an important improvement to 
traditional oral anticoagulation therapy, since they are 
less prone to interpatient variation, have stable pharma-
cokinetic and pharmacodynamic profiles exhibiting less 
interactions, and do not require frequent INR monitor-
ing, thus decreasing or abandoning the need for warfarin 
dosing algorithms (13,49). European Society of Cardiolo-
gy generally gives advantage to NOACs over VKA therapy 
for stroke prevention in AF (50) and treatment of deep 
vein thrombosis (51). While relevant data on NOAC usage 
in B&H are currently not available, the BALKAN-AF survey 
conducted in seven countries, including B&H, reported 
10.1% of all patients on oral anticoagulation therapy to 
be taking NOACs prior to study enrollment. This number 
increased to 17.2% following the enrolling visit or hospi-
talization (52).
The limitations of the present study include the limited 
non-representative sample size of 130 individuals from the 
general population. This study thus does not offer informa-
tion on the risk of thromboembolic events or recommen-
dations for warfarin dosing at the population level. It is also 
important to note that this study alone does not provide 
guidelines regarding the duration or intensity of warfarin 
therapy in Bosnian-Herzegovinian patients. Future research 
should study the prevalence of the major genetic variants, 
including FVL, F2 c.*97G>A (PTM), VKORC1 c.-1639G>A, and 
CYP2C9 variants c.430C>T and c.1075A>C in a study group 
of warfarin-anticoagulated patients and a control group to 
assess their importance for personalization of antithrom-
botic treatment.
This is the first study reporting general population data for 
a panel of 14 genetic variants of inherited thrombophilia 
and warfarin pharmacogenetics in B&H. The results show 
that these genetic variants are considerably present in the 
general population of B&H. The frequency of detected mi-
nor variants is in agreement with previously published data 
for European populations. Implications of this study are im-
portant in that it paves the way for an integrated analysis of 
patient’s unique genomic makeup to offer individualized 
prophylaxis and treatment of thrombotic events.
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